Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-low Expressing Breast Cancer”

39 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 39 results

Not applicableStudy completedNCT06386263
What this trial is testing

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

Who this might be right for
Unresectable Breast CancerMetastatic Breast CancerHER2-low Expressing Breast Cancer+1 more
AstraZeneca 22
Large-scale testing (Phase 3)Not Yet RecruitingNCT06561607
What this trial is testing

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 542
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225
What this trial is testing

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Who this might be right for
Breast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Not applicableLooking for participantsNCT06877416
What this trial is testing

Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer

Who this might be right for
Antibody-drug ConjugatesHER2-low Breast CancerBreast Neoplasms
Sun Yat-sen University 700
Testing effectiveness (Phase 2)Looking for participantsNCT06411457
What this trial is testing

SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 20
Not applicableNot Yet RecruitingNCT06492447
What this trial is testing

Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast Cancer

Who this might be right for
HER 2 Low-expressing Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 50
Testing effectiveness (Phase 2)Looking for participantsNCT05795101
What this trial is testing

TRUDI: TDXD+Durva in HER2+/Low IBC

Who this might be right for
Invasive Breast CancerInflammatory Breast Cancer Stage IIIHER2-positive Breast Cancer+2 more
Filipa Lynce, MD 63
Testing effectiveness (Phase 2)Looking for participantsNCT07498478
What this trial is testing

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

Who this might be right for
Breast Cancer
TransThera Sciences (Nanjing), Inc. 94
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07497386
What this trial is testing

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Who this might be right for
Unresectable Locally Recurrent Breast CancerUnresectable Locally Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07151586
What this trial is testing

Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsNeoplasm MetastasisHER 2 Low-expressing Breast Cancer
UNICANCER 260
Not applicableLooking for participantsNCT07358182
What this trial is testing

Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer

Who this might be right for
Trastuzumab-rezetecanHER2-low Breast CancerHER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 300
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Not applicableNot Yet RecruitingNCT07130344
What this trial is testing

PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer

Who this might be right for
Metastatic Breast CancerHER 2 Low-expressing Breast Cancer
Centre Paul Strauss 262
Large-scale testing (Phase 3)Looking for participantsNCT05904964
What this trial is testing

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Who this might be right for
HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 288
Not applicableLooking for participantsNCT05945732
What this trial is testing

DESTINY Breast Respond HER2-low Europe

Who this might be right for
Unresectable Breast CancerMetastatic Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company 1,155
Testing effectiveness (Phase 2)Looking for participantsNCT06389006
What this trial is testing

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 79
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07150208
What this trial is testing

T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis

Who this might be right for
Breast Cancer With Brain MetastasisHER2-low Expressing Breast Cancer
Fudan University 140
Testing effectiveness (Phase 2)Looking for participantsNCT06227117
What this trial is testing

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 120
Testing effectiveness (Phase 2)Study completedNCT03052634
What this trial is testing

RC48-ADC in Subjects With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
RemeGen Co., Ltd. 112
Testing effectiveness (Phase 2)Study completedNCT01570036
What this trial is testing

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Who this might be right for
Breast Cancer
George E. Peoples 275
Load More Results